CagriSema: Effective Weight Loss for Obesity & Diabetes
- CHICAGO - CagriSema, a combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, taken once weekly, led to important weight loss compared to a placebo, according to researchers.
- The findings come from the REDEFINE 1 trial, which compared CagriSema (Novo Nordisk) to a placebo in overweight or obese patients, and the REDEFINE 2 trial, which compared...
- Davies, professor of diabetes medicine at the University of Leicester, said CagriSema combines a GLP-1 and an amylin analog.
CagriSema, a promising new treatment, is making waves in the fight against obesity and type 2 diabetes. This innovative drug, combining cagrilintide and semaglutide, is showing notable weight loss results. Studies reveal adults with obesity, both with and without diabetes, experienced considerable weight reduction-up to 22.7% in certain specific cases. News Directory 3 reports on this breaking advancement from the REDEFINE 1 and 2 trials, presented at the American Diabetes Association and published in The New England Journal of Medicine. The once-weekly injection is being hailed as a potential game-changer. The trial’s success offers hope for effective weight management strategies. Discover what’s next for this exciting advancement.
CagriSema Shows Promise for Weight Loss in Obese Adults
CHICAGO – CagriSema, a combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, taken once weekly, led to important weight loss compared to a placebo, according to researchers. the study included adults with overweight or obesity, both with and without diabetes.
The findings come from the REDEFINE 1 trial, which compared CagriSema (Novo Nordisk) to a placebo in overweight or obese patients, and the REDEFINE 2 trial, which compared CagriSema to a placebo in obese patients with type 2 diabetes.The results were presented at the American Diabetes Association Scientific Sessions and published in The New England Journal of Medicine.
Melanie J. Davies, professor of diabetes medicine at the University of Leicester, said CagriSema combines a GLP-1 and an amylin analog.
What’s next
Further studies are expected to explore the long-term effects and broader applications of CagriSema in managing obesity and related conditions.